Article Abstract

Neoadjuvant pertuzumab, T-DM1, weekly paclitaxel and possible anthracyclines in HER2 positive early breast cancer treatment— questions from the KRISTINE study

Authors: Jack P. Gleeson, Niamh M. Keegan, Patrick G. Morris

Abstract

For over a decade, the standard of care for early breast cancer that overexpresses human epidermal growth factor 2 (HER2) has been cytotoxic chemotherapy in combination with HER2 targeted agents.